TY - JOUR T1 - CPAnet: the challenges of gaining evidence-based knowledge in chronic pulmonary aspergillosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02879-2021 VL - 59 IS - 4 SP - 2102879 AU - Rosanne Sprute AU - Helmut J.F. Salzer AU - Danila Seidel Y1 - 2022/04/01 UR - http://erj.ersjournals.com/content/59/4/2102879.abstract N2 - The term chronic pulmonary aspergillosis (CPA) is used to describe a wide range of severe chronic fungal infections mainly occurring in non-immunocompromised patients with pre-existing lung disease [1]. CPA is a long-term infection of the lung caused by moulds of the genus Aspergillus. In Europe, the majority of cases are caused by A. fumigatus. About three million people are diagnosed with CPA globally, mostly complicating tuberculosis, allergic bronchopulmonary aspergillosis (ABPA) or sarcoidosis [2].Chronic pulmonary aspergillosis is a destructive fungal disease complicating many respiratory disorders. Evidence is scarce for clinical management decisions. CPAnet aims to improve patient care by collecting data in an international registry. https://bit.ly/3utUFH1This article was written on behalf of all CPAnet members. We thank the ERS for being selected as an ERS Clinical Research Collaboration. ER -